Atum gives labs free access to protein production platform

By The Science Advisory Board staff writers

March 27, 2020 -- Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and resources to battle the COVID-19 pandemic.

The platform contains a variety of viral proteins, antibodies, interleukins, and related protein molecules that are being evaluated in COVID-19 clinical trials. It can also help with the rapid production of commercial-grade protein.

Laboratories can use the platform to develop diagnostic tools, vaccines, and protein-based therapies to help combat the COVID-19 pandemic. Atum is fully operational and currently processing rush orders, the company noted.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here